The first site submitted through the sponsor's designated central IRB--an online portal, a streamlined application that references the already-approved protocol, and a turnaround commitment of seven to 10 business days. Eight days later, the approval letter arrived.

The second site submitted to its academic medical center's institutional IRB. That IRB meets once a month, on the third Thursday. The submission deadline for the next meeting had passed two days earlier. The application sat in queue for three and a half weeks, was reviewed at the following month's meeting, received two stipulations requiring consent form revisions, and was conditionally approved. Final unconditional approval took six weeks from the original submission date.

Same study. Same city. Same regulatory protections for participants. But the coordinator at Site One was preparing for the site initiation visit while the coordinator at Site Two was still waiting for the first IRB meeting.

This is not a story about one model being better than the other. Both IRBs fulfilled their regulatory mandate--reviewing the study for participant protection before authorizing enrollment. The difference is entirely operational: different processes, different timelines, different workflows for the coordinator. And understanding those differences is essential, because as a coordinator you will encounter both models, sometimes simultaneously on different studies, and you need to navigate each one without letting process confusion delay your start-up timeline.

The first site submitted through the sponsor's designated central IRB--an online portal, a streamlined application that references the already-approved protocol, and a turnaround commitment of seven to 10 business days. Eight days later, the approval letter arrived.

The second site submitted to its academic medical center's institutional IRB. That IRB meets once a month, on the third Thursday. The submission deadline for the next meeting had passed two days earlier. The application sat in queue for three and a half weeks, was reviewed at the following month's meeting, received two stipulations requiring consent form revisions, and was conditionally approved. Final unconditional approval took six weeks from the original submission date.

Same study. Same city. Same regulatory protections for participants. But the coordinator at Site One was preparing for the site initiation visit while the coordinator at Site Two was still waiting for the first IRB meeting.

This is not a story about one model being better than the other. Both IRBs fulfilled their regulatory mandate--reviewing the study for participant protection before authorizing enrollment. The difference is entirely operational: different processes, different timelines, different workflows for the coordinator. And understanding those differences is essential, because as a coordinator you will encounter both models, sometimes simultaneously on different studies, and you need to navigate each one without letting process confusion delay your start-up timeline.